Who is sponsoring NCT00436917?

NCT00436917 is sponsored by Mayo Clinic.

What condition does NCT00436917 study?

NCT00436917 studies Breast Cancer, Osteoporosis.

What drugs are being tested in NCT00436917?

Interventions: zoledronic acid, Letrozole as adjuvant therapy.

What is the status of NCT00436917?

NCT00436917 is currently COMPLETED.

Last reviewed 2019-08-28 · How we verify

Zoledronic Acid for Treatment of Osteopenia and Osteoporosis in Women With Primary Breast Cancer Undergoing Adjuvant Aromatase Inhibitor (Letrozole) Therapy

NCT00436917 NA COMPLETED Results posted

RATIONALE: Zoledronate may reduce bone loss in patients receiving letrozole for breast cancer. PURPOSE: This clinical trial is studying how well zoledronate works in treating osteopenia or osteoporosis in postmenopausal women receiving letrozole for stage I, stage II, or stage IIIA primary breast cancer.

Details

Lead sponsor	Mayo Clinic
Phase	NA
Status	COMPLETED
Enrolment	60
Start date	2006-04
Completion	2016-05-09

Conditions

Breast Cancer
Osteoporosis

Interventions

zoledronic acid
Letrozole as adjuvant therapy

Primary outcomes

Average Intra-patient Change in Total Lumbar Spine (L1 to L4) Bone Mineral Density (BMD) — Baseline and 1 year
Change: BMD values at twelve months post study entry minus BMD values at baseline, expressed as a percentage of the baseline value.

Countries

United States